The FDA on August 5, 2020 approved BLENREPĀ® for adult patients with Relapsed or Refractory Multiple Myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a Proteasome Inhibitor, and an Immunomodulatory agent. BLENREPĀ® is a product of GlaxoSmithKline.
Other Pages – Bottom Ad
Advertisement
Subscribe
